Aclaris stock falls after atopic dermatitis trial fails
Aclaris Therapeutics Inc (NASDAQ:ACRS) shares experienced a 6% decline in Monday trading following the announcement that its Phase 2 ADMIRATION trial for atopic dermatitis treatment did not meet its primary and secondary endpoints. The trial, which evaluated bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, aimed to assess its efficacy in patients with moderate-to-severe atopic dermatitis.
While the drug showed target engagement and downregulation of biomarkers related to immune activation, it failed to achieve the desired percent change in Eczema Area and Severity Index score from baseline at Week 24. Aclaris' CEO, Dr. Neal Walker, expressed disappointment in the trial's outcome, stating that the results do not alter the company's development priorities, which remain focused on oral kinase inhibitors and ATI-052, an anti-TSLP/IL-4Rα bispecific antibody.
Additionally, Aclaris has initiated a Phase 2b ALPHA trial of modzatinib (ATI-2138) for moderate-to-severe lichen planus and plans to file an IND for ATI-9494, an oral ITK inhibitor, this quarter, with a Phase 2b trial of ATI-052 in eosinophilic esophagitis set to begin in the first quarter of 2027.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.